tadalafil has been researched along with Hypertension in 29 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (48.28) | 29.6817 |
| 2010's | 6 (20.69) | 24.3611 |
| 2020's | 9 (31.03) | 2.80 |
| Authors | Studies |
|---|---|
| Gupta, A; McGraw, T; Nunes, AP; Seeger, JD; Stewart, A | 1 |
| Kalaitzidis, RG; Nakas, N; Theofilis, P | 1 |
| Gupta, A; Kloner, RA; Kostis, JB; McGraw, TP; Qiu, C | 1 |
| Grossman, E | 1 |
| Hashizume, Y; Ikeda, T; Sato, E; Sato, H; Sekimoto, A; Takahashi, N; Tanaka, K | 1 |
| Dhaun, N; Farrah, TE; Tzoumas, N; Webb, DJ | 1 |
| Higashi, Y; Kamada, S; Kataoka, T; Nagao, Y; Saito, M; Shimizu, S; Shimizu, T | 1 |
| Dal Moro, F; Livi, U; Vendramin, I | 1 |
| Ikeda, T; Katsuragi, S; Kawamura, T; Maki, S; Tachibana, R; Takeuchi, H; Tanaka, H; Tanaka, K; Toriyabe, K; Yoshikawa, K | 1 |
| Aggarwal, S; Ambalavanan, N; Bradley, WE; Carlisle, MA; Dell'Italia, L; Doran, S; Ford, DA; Jilling, T; Lam, A; Lambert, JA; Matalon, S; Patel, RP; Ren, C | 1 |
| Alei, G; Letizia, P; Massoni, F; Ricci, S; Simeone, C | 1 |
| Barbaro, NR; Calhoun, D; Coelho, OR; de Faria, AP; Ferreira-Melo, SE; Fontana, V; Matos-Souza, JR; Modolo, R; Moreno, H; Santos, RC; Yugar-Toledo, JC | 1 |
| Faria, AP; Modolo, R; Moreno, BV; Moreno, H | 1 |
| Cocco, G | 1 |
| Bassi, P; Bonanni, G; Cella, G; De Bon, E; Saggiorato, G | 1 |
| Corona, G; Fusco, F; Mondaini, N; Razzoli, E; Rossi, A; Ungar, A | 1 |
| Emmick, JT; Kloner, RA; Mitchell, M | 1 |
| Schmitt, H; Schulman, CC; Shen, W; Stothard, DR | 1 |
| Hall, TA; McGwin, G; Owsley, C; Vaphiades, MS | 1 |
| Chan, M; Costigan, TM; Hutter, AM; Jackson, G; Kloner, RA; Mittleman, MA; Vail, GM; Warner, MR | 1 |
| Prisant, LM | 1 |
| van Driel, MF | 1 |
| Macdonald, TM; McInnes, GT; Mitchell, MM; Patterson, D; Webster, J | 1 |
| Dinn, RB; Wall, M | 1 |
| Ahuja, S; Goldstein, I; Kim, E; Natanegara, F; Pryor, JL; Steers, WD; Wilde, DW; Wong, DG | 1 |
| Kukreja, RC | 1 |
| Ghiadoni, L; Taddei, S; Versari, D | 1 |
| Liu, ZY; Sun, YH | 1 |
9 review(s) available for tadalafil and Hypertension
| Article | Year |
|---|---|
Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease.
Topics: Cardiovascular Diseases; Erectile Dysfunction; Humans; Hypertension; Male; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Tadalafil | 2020 |
Effects of PDE type 5 inhibitors on left ventricular diastolic dysfunction in resistant hypertension.
Topics: Carbolines; Diastole; Drug Resistance; Heart Failure, Diastolic; Humans; Hypertension; Medical Illustration; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Tadalafil; Treatment Outcome; Ventricular Dysfunction, Left | 2015 |
Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient.
Topics: Algorithms; Carbolines; Cardiovascular Diseases; Diabetes Mellitus; Humans; Hypertension; Imidazoles; Impotence, Vasculogenic; Male; Men's Health; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Pyrimidines; Risk Factors; Sildenafil Citrate; Sulfonamides; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2011 |
Cardiovascular effects of tadalafil in patients on common antihypertensive therapies.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Antihypertensive Agents; Carbolines; Cardiovascular System; Clinical Trials as Topic; Drug Interactions; Erectile Dysfunction; Hemodynamics; Humans; Hypertension; Male; Phosphodiesterase Inhibitors; Tadalafil | 2003 |
Cardiovascular safety update of Tadalafil: retrospective analysis of data from placebo-controlled and open-label clinical trials of Tadalafil with as needed, three times-per-week or once-a-day dosing.
Topics: Aged; Carbolines; Clinical Trials as Topic; Comorbidity; Coronary Artery Disease; Diabetes Mellitus; Dose-Response Relationship, Drug; Drug Administration Schedule; Erectile Dysfunction; Humans; Hyperlipidemias; Hypertension; Male; Middle Aged; Myocardial Infarction; Phosphodiesterase Inhibitors; Retrospective Studies; Tadalafil | 2006 |
Phosphodiesterase-5 inhibitors and their hemodynamic effects.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Antihypertensive Agents; Blood Pressure; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erectile Dysfunction; Humans; Hypertension; Hypotension; Imidazoles; Male; Phosphodiesterase Inhibitors; Piperazines; Purines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vascular Resistance | 2006 |
[Phosphodiesterase inhibitors: effectiveness and new applications].
Topics: Carbolines; Coronary Disease; Erectile Dysfunction; Humans; Hypertension; Imidazoles; Male; Phosphodiesterase Inhibitors; Piperazines; Prostatic Hyperplasia; Pulmonary Disease, Chronic Obstructive; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Triazines; Vardenafil Dihydrochloride | 2006 |
Phosphodiesterase 5 inhibition in essential hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Carbolines; Endothelium; Humans; Hypertension; Imidazoles; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2008 |
[Evaluation of tadalafil for the treatment of erectile dysfunction].
Topics: Carbolines; Diabetes Mellitus; Erectile Dysfunction; Humans; Hypertension; Male; Phosphodiesterase Inhibitors; Tadalafil; Treatment Outcome | 2008 |
5 trial(s) available for tadalafil and Hypertension
| Article | Year |
|---|---|
Tadalafil-induced improvement in left ventricular diastolic function in resistant hypertension.
Topics: Aged; Blood Pressure; Carbolines; Cross-Over Studies; Cyclic GMP; Diastole; Drug Resistance; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Middle Aged; Natriuretic Peptide, Brain; Nitrites; Phosphodiesterase 5 Inhibitors; Single-Blind Method; Tadalafil; Ventricular Dysfunction, Left; Ventricular Function, Left | 2014 |
Erectile dysfunction after therapy with metoprolol: the Hawthorne effect.
Topics: Adrenergic beta-Antagonists; Carbolines; Cross-Over Studies; Drug Interactions; Effect Modifier, Epidemiologic; Erectile Dysfunction; Humans; Hypertension; Male; Metoprolol; Middle Aged; Patient Education as Topic; Phosphodiesterase Inhibitors; Placebo Effect; Tadalafil | 2009 |
Integrated analysis examining first-dose success, success by dose, and maintenance of success among men taking tadalafil for erectile dysfunction.
Topics: Adult; Aged; Aged, 80 and over; Carbolines; Comorbidity; Diabetes Complications; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Erectile Dysfunction; Humans; Hypertension; Male; Middle Aged; Patient Satisfaction; Tadalafil; Treatment Outcome | 2004 |
Influence of a single dose of 20 mg tadalafil, a phosphodiesterase 5 inhibitor, on ambulatory blood pressure in subjects with hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Carbolines; Cross-Over Studies; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Phosphodiesterase Inhibitors; Tadalafil; Treatment Outcome | 2006 |
Efficacy and safety of tadalafil in men with erectile dysfunction with a high prevalence of comorbid conditions: results from MOMENTUS: multiple observations in men with erectile dysfunction in National Tadalafil Study in the US.
Topics: Age Distribution; Aged; Carbolines; Comorbidity; Depression; Diabetes Mellitus; Dose-Response Relationship, Drug; Erectile Dysfunction; Humans; Hypertension; Male; Middle Aged; Penile Erection; Phosphodiesterase Inhibitors; Prevalence; Tadalafil; Treatment Outcome; United States | 2007 |
15 other study(ies) available for tadalafil and Hypertension
| Article | Year |
|---|---|
Retrospective Observational Real-World Outcome Study to Evaluate Safety Among Patients With Erectile Dysfunction (ED) With Co-Possession of Tadalafil and Anti-Hypertensive Medications (anti-HTN).
Topics: Adult; Antihypertensive Agents; Carbolines; Cohort Studies; Erectile Dysfunction; Humans; Hypertension; Male; Outcome Assessment, Health Care; Retrospective Studies; Tadalafil; Treatment Outcome | 2022 |
Tadalafil in patients on antihypertensive medications: Does safety remain an issue?
Topics: Antihypertensive Agents; Humans; Hypertension; Tadalafil | 2022 |
Analysis of integrated clinical safety data of tadalafil in patients receiving concomitant antihypertensive medications.
Topics: Antihypertensive Agents; Double-Blind Method; Erectile Dysfunction; Humans; Hypertension; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Tadalafil; Treatment Outcome | 2022 |
The role of tadalafil in treated hypertensive patients with erectile dysfunction.
Topics: Erectile Dysfunction; Humans; Hypertension; Male; Patient Satisfaction; Tadalafil; Treatment Outcome | 2022 |
Tadalafil alleviates preeclampsia and fetal growth restriction in RUPP model of preeclampsia in mice.
Topics: Animals; Blood Pressure; Disease Models, Animal; Female; Fetal Growth Retardation; Hypertension; Male; Mice; Phosphodiesterase 5 Inhibitors; Pre-Eclampsia; Pregnancy; Tadalafil | 2020 |
Protective effects of tadalafil on prostatic hyperplasia in spontaneously hypertensive rats.
Topics: Animals; Fibroblast Growth Factors; Hypertension; Interleukin-6; Male; Malondialdehyde; Phosphodiesterase 5 Inhibitors; Prostate; Prostatic Hyperplasia; Rats, Inbred SHR; Rats, Inbred WKY; Regional Blood Flow; Tadalafil; Transforming Growth Factor beta1 | 2020 |
The war against the SARS-CoV2 infection: Is it better to fight or mitigate it?
Topics: Angiotensin-Converting Enzyme 2; Animals; Betacoronavirus; Coronavirus Infections; COVID-19; Cytokine Release Syndrome; Estrogens; Humans; Hypertension; Inflammation; Interleukins; Models, Animal; Models, Biological; Nitric Oxide; Obesity; Off-Label Use; Pandemics; Peptidyl-Dipeptidase A; Phosphodiesterase 5 Inhibitors; Pneumonia, Viral; Receptors, Virus; SARS-CoV-2; Sildenafil Citrate; Tadalafil | 2020 |
Maternal tadalafil therapy for fetal growth restriction prevents non-alcoholic fatty liver disease and adipocyte hypertrophy in the offspring.
Topics: Adipocytes; Animals; Diet, High-Fat; Female; Fetal Development; Fetal Growth Retardation; Glucose Tolerance Test; Hypertension; Hypertrophy; Male; Mice; Mice, Inbred C57BL; NG-Nitroarginine Methyl Ester; Non-alcoholic Fatty Liver Disease; Pregnancy; Prenatal Exposure Delayed Effects; Tadalafil | 2021 |
Mechanisms and Treatment of Halogen Inhalation-Induced Pulmonary and Systemic Injuries in Pregnant Mice.
Topics: Animals; Bromine; Disease Models, Animal; Female; Fetal Growth Retardation; Hypertension; Inhalation Exposure; Lung Injury; Mice; Oxidants; Phosphodiesterase 5 Inhibitors; Placenta; Pre-Eclampsia; Pregnancy; Systemic Inflammatory Response Syndrome; Tadalafil; Treatment Outcome | 2017 |
[Medico legal considerations on prosthesis surgery of the erectile dysfunction in a La Peyronie disease case].
Topics: Adult; Carbolines; Diabetes Mellitus, Type 1; Erectile Dysfunction; Foreign-Body Migration; General Surgery; Humans; Hypertension; Intraoperative Complications; Male; Malpractice; Panic Disorder; Penile Implantation; Penile Induration; Penile Prosthesis; Penis; Prosthesis Failure; Tadalafil; Urology | 2013 |
Effects of tadalafil on platelets and endothelium in patients with erectile dysfunction and cardiovascular risk factors: a pilot study.
Topics: Analysis of Variance; Blood Platelets; Carbolines; Cyclic AMP; Cyclic GMP; Dyslipidemias; E-Selectin; Endothelium, Vascular; Erectile Dysfunction; Humans; Hypertension; Male; Middle Aged; Nitric Oxide; P-Selectin; Phosphodiesterase Inhibitors; Pilot Projects; Risk Factors; Smoking; Tadalafil | 2010 |
[Risk classification assures safety].
Topics: Carbolines; Clinical Trials as Topic; Contraindications; Diabetic Angiopathies; Heart Diseases; Humans; Hypertension; Impotence, Vasculogenic; Male; Phosphodiesterase Inhibitors; Risk Assessment; Tadalafil | 2003 |
Non-arteritic anterior ischaemic optic neuropathy and the treatment of erectile dysfunction.
Topics: Carbolines; Case-Control Studies; Erectile Dysfunction; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Optic Neuropathy, Ischemic; Phosphodiesterase Inhibitors; Piperazines; Purines; Retrospective Studies; Sildenafil Citrate; Sulfones; Tadalafil; Vasodilator Agents | 2006 |
Tadalafil associated with typical migraine aura without headache.
Topics: Atrial Fibrillation; Carbolines; Humans; Hypertension; Male; Middle Aged; Migraine with Aura; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil | 2006 |
Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Antihypertensive Agents; Carbolines; Cardiomyopathies; Cardiovascular Agents; Cyclic Nucleotide Phosphodiesterases, Type 5; Disease Models, Animal; Doxorubicin; Endothelium, Vascular; Enzyme Inhibitors; Erectile Dysfunction; Heart Failure; Humans; Hypertension; Hypertension, Pulmonary; Imidazoles; Male; Myocardial Infarction; Myocardial Reperfusion Injury; NG-Nitroarginine Methyl Ester; Nitric Oxide; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents; Ventricular Remodeling | 2007 |